` AJANTPHARM (Ajanta Pharma Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

AJANTPHARM
vs
BSE Sensex 30

Over the past 12 months, AJANTPHARM has outperformed BSE Sensex 30, delivering a return of 21% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
AJANTPHARM vs BSE Sensex 30

Loading

Performance Gap
AJANTPHARM vs BSE Sensex 30

Loading
AJANTPHARM
BSE Sensex 30
Difference

Performance By Year
AJANTPHARM vs BSE Sensex 30

Loading
AJANTPHARM
BSE Sensex 30
Add Stock

Competitors Performance
Ajanta Pharma Ltd vs Peers

BSE Sensex 30
AJANTPHARM
LLY
JNJ
NOVO B
ROG
Add Stock

Ajanta Pharma Ltd
Glance View

Market Cap
334.3B INR
Industry
Pharmaceuticals

In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.

AJANTPHARM Intrinsic Value
1 924.28 INR
Overvaluation 28%
Intrinsic Value
Price
Back to Top